IMRX
Immuneering Corporation$5.16-0.05 (-0.96%)Prev Close$5.21·MCap$194.6M·P/E—·Vol425.0K·Yield—
▲
Buys (12M)
16
$621.8K
▼
Sells (12M)
0
$0.00
◆
Net Activity
Net Buyer
$621.8K
●
Active Insiders
8
last 12 mo
Over the past 12 months, insider activity at Immuneering Corporation (IMRX) has been exclusively buying, with 16 insider purchases totaling $621.8K and 0 insider sales totaling $0.00. The most recent insider transaction was by Zeskind Benjamin J. (director, officer: PRESIDENT AND CEO), who purchased $10.9K worth of shares on Jun 24, 2026. Immuneering Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $194.6M.
IMRX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Zeskind Benjamin J. | director, officer: PRESIDENT AND CEO | Buy | 2,400 | $4.56 | $10.9K | 2,315,252 |
| Jun 16, 2026 | Hall Brett Matthew | officer: CHIEF SCIENTIFIC OFFICER | Buy | 6,035 | $4.15 | $25.0K | 382,531 |
| Jan 20, 2026 | Schall Thomas J. | director | Buy | 21,645 | $4.67 | $101.0K | 74,530+41% |
| Jan 16, 2026 | Brakewood Harold Eugene | Chief Business Officer | Buy | 5,250 | $4.76 | $25.0K | 0 |
| Jan 15, 2026 | Neufeld Leah R | officer: CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 25,970 |
| Jan 15, 2026 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,298 | $4.57 | $10.5K | 0 |
| Jan 15, 2026 | Schall Thomas J. | Director | Buy | 21,645 | $4.67 | $101.0K | 0 |
| Jan 14, 2026 | Feinberg Peter | director | Buy | 20,000 | $4.35 | $86.9K | 135,441 |
| Jan 13, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 0 |
| Jan 12, 2026 | Feinberg Peter | Director | Buy | 20,000 | $4.35 | $86.9K | 0 |
| Oct 3, 2025 | Feinberg Peter | Director | Buy | 7,500 | $6.67 | $50.0K | 0 |
| Oct 1, 2025 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | Buy | 1,020 | $6.83 | $7.0K | 0 |
| Oct 1, 2025 | Morales Mallory | Chief Accounting Officer | Buy | 300 | $6.39 | $1.9K | 0 |
| Oct 1, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 800 | $6.38 | $5.1K | 0 |
| Sep 30, 2025 | Feinberg Peter | Director | Buy | 7,500 | $7.03 | $52.7K | 0 |
| Sep 29, 2025 | Feinberg Peter | Director | Buy | 5,000 | $7.18 | $35.9K | 0 |
| Jul 2, 2025 | HAUSMAN DIANA | Director | Buy | 5,500 | $3.61 | $19.9K | 0 |
| Jul 2, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 700 | $3.57 | $2.5K | 0 |
| Jul 1, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 10,000 | $3.49 | $34.9K | 0 |
| Jun 27, 2025 | Schall Thomas J. | Director | Buy | 9,500 | $3.66 | $34.8K | 0 |
| Jun 20, 2025 | Brakewood Harold Eugene | Chief Business Officer | Buy | 1,900 | $2.53 | $4.8K | 0 |
| Jun 20, 2025 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 13,422 | $2.58 | $34.6K | 0 |
| Jun 18, 2025 | Feinberg Peter | Director | Buy | 25,000 | $2.53 | $63.2K | 0 |
| Jun 18, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 21,000 | $2.39 | $50.1K | 0 |
| Jun 17, 2025 | Schall Thomas J. | Director | Buy | 40,485 | $2.21 | $89.3K | 0 |
| Apr 3, 2024 | Cormorant Asset Management, LP | Sell | 400,000 | $2.90 | $1.16M1.1% OS | 3,295,173 | |
| Mar 25, 2024 | Brakewood Harold Eugene | Chief Business Officer | Buy | 3,900 | $2.57 | $10.0K | 3,900 |
| Mar 25, 2024 | Feinberg Peter | Director | Buy | 25,000 | $2.55 | $63.7K | 111,766+29% |
| Mar 25, 2024 | Morales Mallory | Chief Accounting Officer | Buy | 1,500 | $2.67 | $4.0K | 8,278 |
| Mar 25, 2024 | Schall Thomas J. | Buy | 2,900 | $2.55 | $7.4K | 2,900 | |
| Mar 21, 2024 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 7,000 | $2.86 | $20.0K | 345,896 |
| Mar 21, 2024 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 3,818 | $2.88 | $11.0K | 10,029+61% |
| Mar 19, 2024 | BERMAN ANN E | Director | Buy | 57,965 | $2.13 | $123.4K | 67,465+610% |
| Mar 19, 2024 | Feinberg Peter | Director | Buy | 75,000 | $2.44 | $183.1K | 86,766+637% |
| Mar 19, 2024 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 20,000 | $2.77 | $55.3K | 2,281,852 |
| Mar 18, 2024 | Cormorant Asset Management, LP | Sell | 909,091 | $3.02 | $2.75M2.5% OS | 3,859,098 | |
| May 27, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,551 | $3.92 | $10.0K | 332,685 |
| May 18, 2022 | Bookman Michael | GENERAL COUNSEL AND SECRETARY | Buy | 1,000 | $4.88 | $4.9K | 2,402+71% |
| May 17, 2022 | KEATING LAURIE | Buy | 7,000 | $5.00 | $35.0K | 14,000+100% | |
| May 12, 2022 | Amin Biren | CFO, TREASURER | Buy | 1,000 | $4.42 | $4.4K | 7,898 |
| Mar 24, 2022 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 3,000 | $8.02 | $24.1K | 2,257,352 |
| Mar 23, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 1,050 | $7.91 | $8.3K | 330,134 |
| Mar 22, 2022 | Barrett Scott | CHIEF MEDICAL OFFICER | Buy | 900 | $7.49 | $6.7K | 7,563 |
| Mar 16, 2022 | Feinberg Peter | Buy | 6,667 | $6.75 | $45.0K | 11,766+131% | |
| Mar 15, 2022 | BERMAN ANN E | Buy | 6,000 | $6.40 | $38.4K | 9,500+171% | |
| Sep 21, 2021 | Feinberg Peter | Buy | 4,750 | $24.45 | $116.1K | 5,099New Position | |
| Sep 15, 2021 | Feinberg Peter | Buy | 6,099 | $21.50 | $131.1K | 392,242 | |
| Sep 14, 2021 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 2,083 | $22.87 | $47.6K | 2,602,352 |
| Aug 5, 2021 | Cormorant Asset Management, LP | Buy | 550,000 | $15.00 | $8.25M1.5% OS | 2,252,628+32% | |
| Aug 4, 2021 | Amin Biren | CFO, Treasurer | Buy | 4,175 | $15.00 | $62.6K | 6,898+153% |
Showing 1–50 of 58
1 / 2
IMRX Insider Buying Activity
The following table shows recent insider purchases of Immuneering Corporation (IMRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Jun 24, 2026 | Zeskind Benjamin J. | director, officer: PRESIDENT AND CEO | Buy | 2,400 | $4.56 | $10.9K | 2,315,252 |
| Jun 16, 2026 | Hall Brett Matthew | officer: CHIEF SCIENTIFIC OFFICER | Buy | 6,035 | $4.15 | $25.0K | 382,531 |
| Jan 20, 2026 | Schall Thomas J. | director | Buy | 21,645 | $4.67 | $101.0K | 74,530+41% |
| Jan 16, 2026 | Brakewood Harold Eugene | Chief Business Officer | Buy | 5,250 | $4.76 | $25.0K | 0 |
| Jan 15, 2026 | Neufeld Leah R | officer: CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 25,970 |
| Jan 15, 2026 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,298 | $4.57 | $10.5K | 0 |
| Jan 15, 2026 | Schall Thomas J. | Director | Buy | 21,645 | $4.67 | $101.0K | 0 |
| Jan 14, 2026 | Feinberg Peter | director | Buy | 20,000 | $4.35 | $86.9K | 135,441 |
| Jan 13, 2026 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 2,626 | $4.15 | $10.9K | 0 |
| Jan 12, 2026 | Feinberg Peter | Director | Buy | 20,000 | $4.35 | $86.9K | 0 |
| Oct 3, 2025 | Feinberg Peter | Director | Buy | 7,500 | $6.67 | $50.0K | 0 |
| Oct 1, 2025 | Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY | Buy | 1,020 | $6.83 | $7.0K | 0 |
| Oct 1, 2025 | Morales Mallory | Chief Accounting Officer | Buy | 300 | $6.39 | $1.9K | 0 |
| Oct 1, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 800 | $6.38 | $5.1K | 0 |
| Sep 30, 2025 | Feinberg Peter | Director | Buy | 7,500 | $7.03 | $52.7K | 0 |
| Sep 29, 2025 | Feinberg Peter | Director | Buy | 5,000 | $7.18 | $35.9K | 0 |
| Jul 2, 2025 | HAUSMAN DIANA | Director | Buy | 5,500 | $3.61 | $19.9K | 0 |
| Jul 2, 2025 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 700 | $3.57 | $2.5K | 0 |
| Jul 1, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 10,000 | $3.49 | $34.9K | 0 |
| Jun 27, 2025 | Schall Thomas J. | Director | Buy | 9,500 | $3.66 | $34.8K | 0 |
| Jun 20, 2025 | Brakewood Harold Eugene | Chief Business Officer | Buy | 1,900 | $2.53 | $4.8K | 0 |
| Jun 20, 2025 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 13,422 | $2.58 | $34.6K | 0 |
| Jun 18, 2025 | Feinberg Peter | Director | Buy | 25,000 | $2.53 | $63.2K | 0 |
| Jun 18, 2025 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 21,000 | $2.39 | $50.1K | 0 |
| Jun 17, 2025 | Schall Thomas J. | Director | Buy | 40,485 | $2.21 | $89.3K | 0 |
| Mar 25, 2024 | Brakewood Harold Eugene | Chief Business Officer | Buy | 3,900 | $2.57 | $10.0K | 3,900 |
| Mar 25, 2024 | Feinberg Peter | Director | Buy | 25,000 | $2.55 | $63.7K | 111,766+29% |
| Mar 25, 2024 | Morales Mallory | Chief Accounting Officer | Buy | 1,500 | $2.67 | $4.0K | 8,278 |
| Mar 25, 2024 | Schall Thomas J. | Buy | 2,900 | $2.55 | $7.4K | 2,900 | |
| Mar 21, 2024 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 7,000 | $2.86 | $20.0K | 345,896 |
| Mar 21, 2024 | Neufeld Leah R | CHIEF PEOPLE OFFICER | Buy | 3,818 | $2.88 | $11.0K | 10,029+61% |
| Mar 19, 2024 | BERMAN ANN E | Director | Buy | 57,965 | $2.13 | $123.4K | 67,465+610% |
| Mar 19, 2024 | Feinberg Peter | Director | Buy | 75,000 | $2.44 | $183.1K | 86,766+637% |
| Mar 19, 2024 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 20,000 | $2.77 | $55.3K | 2,281,852 |
| May 27, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 2,551 | $3.92 | $10.0K | 332,685 |
| May 18, 2022 | Bookman Michael | GENERAL COUNSEL AND SECRETARY | Buy | 1,000 | $4.88 | $4.9K | 2,402+71% |
| May 17, 2022 | KEATING LAURIE | Buy | 7,000 | $5.00 | $35.0K | 14,000+100% | |
| May 12, 2022 | Amin Biren | CFO, TREASURER | Buy | 1,000 | $4.42 | $4.4K | 7,898 |
| Mar 24, 2022 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 3,000 | $8.02 | $24.1K | 2,257,352 |
| Mar 23, 2022 | Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER | Buy | 1,050 | $7.91 | $8.3K | 330,134 |
| Mar 22, 2022 | Barrett Scott | CHIEF MEDICAL OFFICER | Buy | 900 | $7.49 | $6.7K | 7,563 |
| Mar 16, 2022 | Feinberg Peter | Buy | 6,667 | $6.75 | $45.0K | 11,766+131% | |
| Mar 15, 2022 | BERMAN ANN E | Buy | 6,000 | $6.40 | $38.4K | 9,500+171% | |
| Sep 21, 2021 | Feinberg Peter | Buy | 4,750 | $24.45 | $116.1K | 5,099New Position | |
| Sep 15, 2021 | Feinberg Peter | Buy | 6,099 | $21.50 | $131.1K | 392,242 | |
| Sep 14, 2021 | Zeskind Benjamin J. | PRESIDENT AND CEO | Buy | 2,083 | $22.87 | $47.6K | 2,602,352 |
| Aug 5, 2021 | Cormorant Asset Management, LP | Buy | 550,000 | $15.00 | $8.25M1.5% OS | 2,252,628+32% | |
| Aug 4, 2021 | Amin Biren | CFO, Treasurer | Buy | 4,175 | $15.00 | $62.6K | 6,898+153% |
IMRX Insider Selling Activity
The following table shows recent insider sales of Immuneering Corporation (IMRX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Apr 3, 2024 | Cormorant Asset Management, LP | Sell | 400,000 | $2.90 | $1.16M1.1% OS | 3,295,173 | |
| Mar 18, 2024 | Cormorant Asset Management, LP | Sell | 909,091 | $3.02 | $2.75M2.5% OS | 3,859,098 |
IMRX Insiders
Similar Stocks to IMRX
VRTX
Vertex Pharmaceuticals Incorporated
$476.29+0.08%
$126.50B
REGN
Regeneron Pharmaceuticals, Inc.
$662.73+1.01%
$68.29B
ALNY
Alnylam Pharmaceuticals, Inc.
$275.93-1.72%
$43.19B
RVMD
Revolution Medicines, Inc.
$185.71+0.42%
$40.34B
MRNA
Moderna, Inc.
$68.11+1.00%
$27.09B
INSM
Insmed Incorporated
$109.25-0.67%
$25.06B
INCY
Incyte Corporation
$114.43-0.30%
$23.32B
UTHR
United Therapeutics Corporation
$530.63+0.75%
$23.22B